Supernus Pharmaceuticals Inc (SUPN) 7.57 $SUPN
Supernus Announces First Quarter 2014 Results
GlobeNewswire - Mon May 12, 4:38PM CDT
-- First quarter product prescriptions, as reported by IMS, totaled 30,208, increasing by 9,098, or 43%, as compared to fourth quarter 2013.
Supernus to Host First Quarter 2014 Earnings Conference Call
GlobeNewswire - Tue Apr 29, 6:30AM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report the quarter ending March 31, 2014 financial results after the close of the U.S. financial markets Monday, May 12, 2014.
Is Supernus Pharmaceuticals (SUPN) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:39AM CDT
Supernus Pharmaceuticals (SUPN) in the Medical - Generic Drugs space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
4 Stocks Under $10 Making Big Moves
at The Street - Mon Mar 17, 6:46AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Why Supernus Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 13, 11:59AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Supernus Pharmaceuticals , a specialty...
Supernus Pharmaceuticals wins third US patent for antiepileptic drug Trokendi XR, with protection no earlier than 2027
M2 - Thu Mar 13, 3:55AM CDT
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) reported on Wednesday the receipt of the third patent (number 8,663,683) in the US, covering its novel once-daily extended-release topiramate product, Trokendi XR.
Supernus Pharmaceuticals posts higher net loss of USD92.3m in 2013
M2 - Thu Mar 13, 3:26AM CDT
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) announced on Wednesday its net loss of USD92.3m (USD2.90 per share) for the full year 2013.
Supernus Announces Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
-- Product prescriptions filled at the pharmacy level in the fourth quarter of 2013 increased by 12,527, or more than 100%, as compared to third quarter.
Supernus Announces Issuance of Third US Patent Protecting Trokendi XR(TM)
Business Wire - Wed Mar 12, 6:30AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a third patent (number 8,663,683) by the United States Patent and Trademark Office (USPTO) covering Trokendi XR(TM), its novel once-daily extended-release topiramate product. The patent was issued by the USPTO on March 04, 2014. It provides protection for the product with expiration that is no earlier than 2027.
Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call
Business Wire - Tue Feb 25, 6:30AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report fourth quarter and full year 2013 financial results after the market closes Wednesday, March 12, 2014. CEO, Jack Khattar, and CFO, Greg Patrick, will be hosting a conference call on Thursday, March 13, 2014 at 9:00 AM Eastern Time, to discuss 2013 financial results and to provide a business update.
Supernus to Present at Cowen and Company Healthcare Conference in March
Business Wire - Thu Feb 20, 6:30AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company's management will provide a business update on the Company at the Cowen and Company Healthcare Conference.
Supernus at Citibank and RBC Global Healthcare Conferences in February
Business Wire - Fri Feb 07, 6:30AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company's management will be hosting investor meetings during Citi's 2014 Global Healthcare Conference.
Supernus Announces Publication of Phase III Study (PROSPER) Results on Oxtellar XR(R)
Business Wire - Mon Feb 03, 6:30AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company, today announced the publication of the Prospective, Randomized Study of Oxcarbazepine extended release in Subjects with Partial Epilepsy Refractory (PROSPER) data on Oxtellar XR. Results of this Phase III pivotal trial will appear in the upcoming March issue of Acta Neurologica Scandinavica, Volume 129, Issue 3, pages 143-153 and is available online at http://onlinelibrary.wiley.com/doi/10.1111/an...7/abstract.
Supernus Pharmaceuticals Inc wins patents for novel non-stimulant ADHD product SPN-812
M2 - Tue Jan 28, 6:12AM CST
Pharmaceutical company Supernus Pharmaceuticals Inc (NasdaqGM:SUPN) reported on Monday the receipt of patents for SPN-812 for the treatment of ADHD in Europe in Canada.
Supernus Announces Issuance of First Use Patents Protecting SPN-812 as a Novel Non-Stimulant ADHD Product
GlobeNewswire - Mon Jan 27, 8:00AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of a European patent (number 2341912) and Canadian patent (number 2,735,934) for SPN-812, its novel non-stimulant product candidate for the treatment of ADHD. These patents will provide protection for the product with expiration that is no earlier than 2029. Supernus has several additional patent applications for SPN-812 pending in other geographic regions, including the United States.
Supernus' Oxtellar XR Gets 3rd U.S. Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 08, 10:20AM CST
The U.S. Patent and Trademark Office (USPTO) recently issued a new U.S. patent (Patent No. 8,617,600) to Supernus Pharma's Oxtellar XR
Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
PR Newswire - Wed Jan 08, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Eli Lilly & Co. (NYSE: LLY), Allergan Inc. (NYSE: AGN), Waters Corp. (NYSE: WAT), Novavax, Inc. (NASDAQ: NVAX), and Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Supernus Pharmaceuticals Inc wins third US patent for Oxtellar XR for the treatment of epilepsy
M2 - Wed Jan 08, 4:37AM CST
Specialist pharmaceutical company Supernus Pharmaceuticals Inc (NasdaqGM:SUPN) revealed on Tuesday the receipt of a third patent covering its novel once-daily extended-release oxcarbazepine product, Oxtellar XR.
Supernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R)
GlobeNewswire - Tue Jan 07, 8:00AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of a third patent (number 8,617,600) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR(R), its novel once-daily extended-release oxcarbazepine product. The patent was issued by the USPTO on December 31, 2013. It provides protection for the product with expiration that is no earlier than 2027.
Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jan 02, 9:48AM CST
Altogether it was a slow week for the biotech sector though companies like UTHR made the headlines.
Supernus Announces First Quarter 2014 Results
GlobeNewswire - Mon May 12, 4:38PM CDT
-- First quarter product prescriptions, as reported by IMS, totaled 30,208, increasing by 9,098, or 43%, as compared to fourth quarter 2013.
Supernus to Host First Quarter 2014 Earnings Conference Call
GlobeNewswire - Tue Apr 29, 6:30AM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report the quarter ending March 31, 2014 financial results after the close of the U.S. financial markets Monday, May 12, 2014.
Is Supernus Pharmaceuticals (SUPN) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:39AM CDT
Supernus Pharmaceuticals (SUPN) in the Medical - Generic Drugs space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
4 Stocks Under $10 Making Big Moves
at The Street - Mon Mar 17, 6:46AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Why Supernus Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 13, 11:59AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Supernus Pharmaceuticals , a specialty...
Supernus Pharmaceuticals wins third US patent for antiepileptic drug Trokendi XR, with protection no earlier than 2027
M2 - Thu Mar 13, 3:55AM CDT
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) reported on Wednesday the receipt of the third patent (number 8,663,683) in the US, covering its novel once-daily extended-release topiramate product, Trokendi XR.
Supernus Pharmaceuticals posts higher net loss of USD92.3m in 2013
M2 - Thu Mar 13, 3:26AM CDT
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) announced on Wednesday its net loss of USD92.3m (USD2.90 per share) for the full year 2013.
Supernus Announces Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Wed Mar 12, 3:30PM CDT
-- Product prescriptions filled at the pharmacy level in the fourth quarter of 2013 increased by 12,527, or more than 100%, as compared to third quarter.
Supernus Announces Issuance of Third US Patent Protecting Trokendi XR(TM)
Business Wire - Wed Mar 12, 6:30AM CDT
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a third patent (number 8,663,683) by the United States Patent and Trademark Office (USPTO) covering Trokendi XR(TM), its novel once-daily extended-release topiramate product. The patent was issued by the USPTO on March 04, 2014. It provides protection for the product with expiration that is no earlier than 2027.
Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call
Business Wire - Tue Feb 25, 6:30AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report fourth quarter and full year 2013 financial results after the market closes Wednesday, March 12, 2014. CEO, Jack Khattar, and CFO, Greg Patrick, will be hosting a conference call on Thursday, March 13, 2014 at 9:00 AM Eastern Time, to discuss 2013 financial results and to provide a business update.
Supernus to Present at Cowen and Company Healthcare Conference in March
Business Wire - Thu Feb 20, 6:30AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company's management will provide a business update on the Company at the Cowen and Company Healthcare Conference.
Supernus at Citibank and RBC Global Healthcare Conferences in February
Business Wire - Fri Feb 07, 6:30AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company's management will be hosting investor meetings during Citi's 2014 Global Healthcare Conference.
Supernus Announces Publication of Phase III Study (PROSPER) Results on Oxtellar XR(R)
Business Wire - Mon Feb 03, 6:30AM CST
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company, today announced the publication of the Prospective, Randomized Study of Oxcarbazepine extended release in Subjects with Partial Epilepsy Refractory (PROSPER) data on Oxtellar XR. Results of this Phase III pivotal trial will appear in the upcoming March issue of Acta Neurologica Scandinavica, Volume 129, Issue 3, pages 143-153 and is available online at http://onlinelibrary.wiley.com/doi/10.1111/an...7/abstract.
Supernus Pharmaceuticals Inc wins patents for novel non-stimulant ADHD product SPN-812
M2 - Tue Jan 28, 6:12AM CST
Pharmaceutical company Supernus Pharmaceuticals Inc (NasdaqGM:SUPN) reported on Monday the receipt of patents for SPN-812 for the treatment of ADHD in Europe in Canada.
Supernus Announces Issuance of First Use Patents Protecting SPN-812 as a Novel Non-Stimulant ADHD Product
GlobeNewswire - Mon Jan 27, 8:00AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of a European patent (number 2341912) and Canadian patent (number 2,735,934) for SPN-812, its novel non-stimulant product candidate for the treatment of ADHD. These patents will provide protection for the product with expiration that is no earlier than 2029. Supernus has several additional patent applications for SPN-812 pending in other geographic regions, including the United States.
Supernus' Oxtellar XR Gets 3rd U.S. Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 08, 10:20AM CST
The U.S. Patent and Trademark Office (USPTO) recently issued a new U.S. patent (Patent No. 8,617,600) to Supernus Pharma's Oxtellar XR
Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
PR Newswire - Wed Jan 08, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Eli Lilly & Co. (NYSE: LLY), Allergan Inc. (NYSE: AGN), Waters Corp. (NYSE: WAT), Novavax, Inc. (NASDAQ: NVAX), and Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Supernus Pharmaceuticals Inc wins third US patent for Oxtellar XR for the treatment of epilepsy
M2 - Wed Jan 08, 4:37AM CST
Specialist pharmaceutical company Supernus Pharmaceuticals Inc (NasdaqGM:SUPN) revealed on Tuesday the receipt of a third patent covering its novel once-daily extended-release oxcarbazepine product, Oxtellar XR.
Supernus Announces Issuance of Third US Patent Protecting Oxtellar XR(R)
GlobeNewswire - Tue Jan 07, 8:00AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of a third patent (number 8,617,600) by the United States Patent and Trademark Office (USPTO) covering Oxtellar XR(R), its novel once-daily extended-release oxcarbazepine product. The patent was issued by the USPTO on December 31, 2013. It provides protection for the product with expiration that is no earlier than 2027.
Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Jan 02, 9:48AM CST
Altogether it was a slow week for the biotech sector though companies like UTHR made the headlines.
